iRhythm (IRTC): Buy, Sell, or Hold Post Q4 Earnings?

iRhythm has gotten torched over the last six months - since October 2025, its stock price has dropped 31.2% to $125.18 per share. This might have investors contemplating their next move.

Following the pullback, is now the time to buy IRTC? Find out in our full research report, it’s free.

Why Does IRTC Stock Spark Debate?

Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.

Two Things to Like:

1. Skyrocketing Revenue Shows Strong Momentum

A company’s long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, iRhythm’s sales grew at an excellent 23% compounded annual growth rate over the last five years. Its growth surpassed the average healthcare company and shows its offerings resonate with customers.

2. Increasing Free Cash Flow Margin Juices Financials

If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.

As you can see below, iRhythm’s margin expanded by 25 percentage points over the last five years. iRhythm’s free cash flow margin for the trailing 12 months was 4.6%.

One Reason to be Careful:

Fewer Distribution Channels Limit its Ceiling

Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.

With just $747.1 million in revenue over the past 12 months, iRhythm is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. On the bright side, iRhythm’s smaller revenue base allows it to grow faster if it can execute well.

Final Judgment

iRhythm’s positive characteristics outweigh the negatives. With the recent decline, the stock trades at 40.7× forward EV-to-EBITDA (or $125.18 per share). Is now a good time to buy? See for yourself in our full research report, it’s free.

Stocks We Like Even More Than iRhythm

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.